SparingVision’s €44.5 Million Series A2 Fundraising

SparingVision's €44.5 Million Series A2 Fundraising

Dechert advised the investors in the transaction. Wilson Sonsini Goodrich & Rosati advised SparingVision on the deal.

SparingVision completed its €44.5 million Series A2 fundraising, with UPMC Enterprises, 4Bio Capital and Ysios Capital acting as investors.

SparingVision is a biotechnology company specialized in the research and development of an innovative therapeutic approach for the treatment of inherited retinal degenerative diseases such as retinitis pigmentosa.

Dechert advised the investors on legal aspects with, in corporate, partner Anne-Charlotte Rivière (Picture), with Aude Steinberg and Johann Gandilhon, associates, in intellectual property, Marie Fillon, national partner with Louis de Chezelles, associate, in labor, Thibault Meiers, national partner with Maëlle Chausse, associate.

The Wilson Sonsini team was led by Michael Hostetler, Greg Mitchell, and Brett Zirkle, and the technology transactions team of Lauren Wardle and Miranda Biven.

Involved fees earner: Maëlle Chausse – Dechert; Louis de Chezelles – Dechert; Marie Fillon – Dechert; Johann Gandilhon – Dechert; Thibault Meiers – Dechert; Anne-Charlotte Rivière – Dechert; Aude Steinberg – Dechert; Miranda Biven – Wilson Sonsini Goodrich & Rosati; Michael Hostetler – Wilson Sonsini Goodrich & Rosati; Gregory Mitchell – Wilson Sonsini Goodrich & Rosati; Lauren Wardle – Wilson Sonsini Goodrich & Rosati; Brett Zirkle – Wilson Sonsini Goodrich & Rosati;

Law Firms: Dechert; Wilson Sonsini Goodrich & Rosati;

Clients: 4Bio Capital; SparingVision SAS; UPMC Enterprises; Ysios Capital;

Author: Ambrogio Visconti